SPOTLIGHT -
First therapy approved for “off” episodes in advanced Parkinson’s disease
Employers Face Barriers With Adopting Biosimilars
Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
Amber Specialty, Hy-Vee to Dispense Regeneron Monoclonal Antibody for COVID-19
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
Point32Health Selects OptumRx for PBM Services
Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.
AllianceRx Walgreens Prime Home Delivery Earns Reaccreditation
The accreditation is effective through July 2024.
Non-opioid Pain Therapeutic Achieves More Than 100 Formulary Approvals
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
Top 5 drugs in the pipeline
Some of the top medications were approved this summer, while others are awaiting FDA approval.
